On­col­o­gy biotech Ac­cent rais­es $75M to en­ter the clin­ic

Ac­cent Ther­a­peu­tics raised $75 mil­lion in Se­ries C fund­ing from three Big Phar­ma com­pa­nies and oth­er in­vestors to test its first two pre­ci­sion on­col­o­gy small mol­e­cules in ear­ly clin­i­cal tri­als.

The raise, led by glob­al as­set firm Mi­rae’s new US af­fil­i­ate, which is ded­i­cat­ed to life sci­ences, oc­curred near­ly four years af­ter the start­up dis­closed a $63 mil­lion Se­ries B in the ear­ly days of the pan­dem­ic.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER